Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients

Table 2 Univariate analysis of associations with clinical outcomes

Variables	Total	Event	Median survival (mo)	Log-rank P	HR (95% CI)	P
Association with PFS
CTC
0	26	14	18.1	< 0.001	Ref.
≥ 1	37	31	5.0		4.02 (2.05–7.86)	< 0.001
NLR
< 2.65	21	14	11.4	0.119	Ref.
≥ 2.65	42	31	6.5		1.65 (0.87–3.12)	0.123
PLR
< 155.54	23	14	11.4	0.091	Ref.
≥ 155.54	40	31	5.7		1.72 (0.91–3.24)	0.095
Risk group
CTC = 0 and NLR < 2.65	9	4	20.1	< 0.001	Ref.
CTC = 0 and NLR ≥ 2.65	17	10	12.2		1.92 (0.59–6.29)	0.279
CTC ≥ 1 and NLR < 2.65	12	10	6.1		Ref.
CTC ≥ 1 and NLR ≥ 2.65	25	21	3.3		2.12 (0.97–4.61)	0.059
CTC = 0 and PLR < 155.54	11	5	20.1	< 0.001	Ref.
CTC = 0 and PLR ≥ 155.54	15	9	17.9		1.42 (0.47–4.29)	0.531
CTC ≥ 1 and PLR < 155.54	12	9	7.5		Ref.
CTC ≥ 1 and PLR ≥ 155.54	25	22	4.1		2.27 (1.02–5.08)	0.046
Association with OS
CTC
0	26	5	NR	0.006	Ref.
≥ 1	37	18	14.2		3.72 (1.37–10.06)	0.010
NLR
< 2.65	21	4	NR	0.023	Ref.
≥ 2.65	42	19	17.7		3.27 (1.11–9.63)	0.031
PLR
< 155.54	23	5	NR	0.077	Ref.
≥ 155.54	40	18	17.7		2.38 (0.88–6.43)	0.086
Risk group
CTC = 0 and NLR < 2.65	9	1	NR	0.002	Ref.
CTC = 0 and NLR ≥ 2.65	17	4	NR		3.12 (0.34–28.34)	0.313
CTC ≥ 1 and NLR < 2.65	12	3	NR		Ref.
CTC ≥ 1 and NLR ≥ 2.65	25	15	9.1		3.79 (1.09–13.13)	0.036
CTC = 0 and PLR < 155.54	11	2	NR	0.007	Ref.
CTC = 0 and PLR ≥ 155.54	15	3	NR		1.19 (0.20–7.18)	0.846
CTC ≥ 1 and PLR < 155.54	12	3	NR		Ref.
CTC ≥ 1 and PLR ≥ 155.54	25	15	13.7		2.85 (0.82–9.86)	0.098

CTC circulating tumor cell; NLR neutrophil-to-lymphocyte ratio; PLR platelet-to-lymphocyte ratio; PFS progression free survival; OS overall survival; NR not reached; HR hazard ratio; CI confidence interval

ISSN: 1471-2407